Nanobiotix Shares Up +750% Over a Year, But Down 8% in a Week
Nanobiotix is down 2.03% this Monday mid-session, at 25.06 euros, in a declining Parisian market. The biotech specialized in nanomedicine, however, shows a spectacular performance over a year, with a jump of nearly 750%. Today's decline is part of an already difficult week for the stock, which has lost more than 8% over seven days.
Current Trading Situation of Nanobiotix Shares
Nanobiotix shares are currently trading at 25.06 euros, down from last Friday's close of 25.58 euros. Despite this decline, the recent trajectory remains remarkable: the stock still shows a gain of over 45% over three months and an increase of nearly 750% over twelve months. Technically, the price is now moving in the lower part of its Bollinger Bands, close to the lower limit set at 24.41 euros, indicating a potential oversold zone. The RSI, at 48, remains in neutral territory, with no marked reversal signal. Moreover, the 50-day moving average (24.51 euros) is a technical level to watch: the price is approaching it, while the identified support is at 22.95 euros. The decline over the past week could be a technical consolidation after the bullish acceleration of recent months, with the 20-day moving average (26.92 euros) now above the current price.
Market Context of Nanobiotix's Decline
Nanobiotix's decline is part of a generally negative market context this Monday. The CAC 40 is down 0.87% in session, at 8188 points, while the SBF 120 loses in the same proportions. Health sector stocks are no exception: Sanofi is down 1.21% and UCB loses 0.91% at the same time. Geopolitical tensions related to the announcement of a US naval blockade against Iran weigh on all European markets. The surge in oil prices above 100 dollars a barrel creates a risk-averse climate that particularly penalizes small and medium biotechnological capitalizations, whose revenue prospects are naturally more distant in time. The negative beta of the stock (-0.72) indicates, however, that Nanobiotix historically shows an inverse correlation with the market. The high monthly volatility, at 23.46%, reminds that the amplitude of variation on this type of stock remains significant, regardless of general market movements.
